Gene therapy and stem cell therapy for cardiovascular diseases today: a model for translational research

2007 ◽  
Vol 4 (S1) ◽  
pp. S1-S8 ◽  
Author(s):  
Valentin Fuster ◽  
Javier Sanz
Keyword(s):  
Gene Therapy ◽  
Stem Cell ◽  
Cardiovascular Diseases ◽  
Cell Therapy ◽  
Translational Research ◽  
Stem Cell Therapy

Stem Cell Therapy in Cardiovascular Diseases

2015 ◽  
pp. 184-184 ◽  
Author(s):  
Ajay Bahl ◽  
Hamed Bashir ◽  
KK Talwar
Keyword(s):  
Stem Cell ◽  
Cardiovascular Diseases ◽  
Cell Therapy ◽  
Stem Cell Therapy

scholarly journals Improving stem cell therapy in cardiovascular diseases: the potential role of microRNA

2016 ◽  
Vol 311 (1) ◽  
pp. H207-H218 ◽  
Author(s):  
Evelien Nollet ◽  
Vicky Y. Hoymans ◽  
Amaryllis H. Van Craenenbroeck ◽  
Christiaan J. Vrints ◽  
Emeline M. Van Craenenbroeck
Keyword(s):  
Bone Marrow ◽  
Stem Cell ◽  
Cardiovascular Diseases ◽  
Cell Therapy ◽  
Progenitor Cells ◽  
Stem Cell Therapy ◽  
Cell Function ◽  
Current Evidence ◽  
Comprehensive Overview ◽  
Vascular Regeneration

The initial promising prospect of autologous bone marrow-derived stem cell therapy in the setting of cardiovascular diseases has been overshadowed by functional shortcomings of the stem cell product. As powerful epigenetic regulators of (stem) cell function, microRNAs are valuable targets for novel therapeutic strategies. Indeed, modulation of specific miRNA expression could contribute to improved therapeutic efficacy of stem cell therapy. First, this review elaborates on the functional relevance of miRNA dysregulation in bone marrow-derived progenitor cells in different cardiovascular diseases. Next, we provide a comprehensive overview of the current evidence on the effect of specific miRNA modulation in several types of progenitor cells on cardiac and/or vascular regeneration. By elaborating on the cardioprotective regulation of progenitor cells on cardiac miRNAs, more insight in the underlying mechanisms of stem cell therapy is provided. Finally, some considerations are made regarding the potential of circulating miRNAs as regulators of the miRNA signature of progenitor cells in cardiovascular diseases.

scholarly journals Mechanism and Prevention of Spiral Ganglion Neuron Degeneration in the Cochlea

2022 ◽  
Vol 15 ◽  
Author(s):  
Li Zhang ◽  
Sen Chen ◽  
Yu Sun
Keyword(s):  
Gene Therapy ◽  
Hearing Loss ◽  
Stem Cell ◽  
Cell Therapy ◽  
Sensory Neurons ◽  
Stem Cell Therapy ◽  
Spiral Ganglion ◽  
Spiral Ganglion Neuron ◽  
Regeneration Ability ◽  
Ganglion Neurons

Sensorineural hearing loss (SNHL) is one of the most prevalent sensory deficits in humans, and approximately 360 million people worldwide are affected. The current treatment option for severe to profound hearing loss is cochlear implantation (CI), but its treatment efficacy is related to the survival of spiral ganglion neurons (SGNs). SGNs are the primary sensory neurons, transmitting complex acoustic information from hair cells to second-order sensory neurons in the cochlear nucleus. In mammals, SGNs have very limited regeneration ability, and SGN loss causes irreversible hearing loss. In most cases of SNHL, SGN damage is the dominant pathogenesis, and it could be caused by noise exposure, ototoxic drugs, hereditary defects, presbycusis, etc. Tremendous efforts have been made to identify novel treatments to prevent or reverse the damage to SGNs, including gene therapy and stem cell therapy. This review summarizes the major causes and the corresponding mechanisms of SGN loss and the current protection strategies, especially gene therapy and stem cell therapy, to promote the development of new therapeutic methods.

Sign in / Sign up

Export Citation Format

Share Document